1. Home
  2. PMO vs EOLS Comparison

PMO vs EOLS Comparison

Compare PMO & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Municipal Opportunities Trust

PMO

Putnam Municipal Opportunities Trust

N/A

Current Price

$10.70

Market Cap

292.9M

Sector

Finance

ML Signal

N/A

Logo Evolus Inc.

EOLS

Evolus Inc.

N/A

Current Price

$4.26

Market Cap

304.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMO
EOLS
Founded
1993
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
292.9M
304.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PMO
EOLS
Price
$10.70
$4.26
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.40
AVG Volume (30 Days)
65.4K
847.1K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
4.10%
N/A
EPS Growth
N/A
25.00
EPS
0.42
N/A
Revenue
N/A
$266,274,000.00
Revenue This Year
N/A
$13.57
Revenue Next Year
N/A
$11.39
P/E Ratio
$25.49
N/A
Revenue Growth
N/A
31.76
52 Week Low
$9.56
$4.09
52 Week High
$10.79
$14.93

Technical Indicators

Market Signals
Indicator
PMO
EOLS
Relative Strength Index (RSI) 58.43 34.83
Support Level $10.30 $4.09
Resistance Level $10.75 $4.99
Average True Range (ATR) 0.08 0.22
MACD 0.00 0.06
Stochastic Oscillator 73.95 34.29

Price Performance

Historical Comparison
PMO
EOLS

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: